Regenerative Meds: Indian Drug Makers Inject New Life Through Investments In Stem Cells
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Leading Indian companies are gearing up for emerging frontiers in medicine research, and among all the segments, regenerative therapies seem to be driving more and more initial investments from mainstream pharma companies
You may also be interested in...
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes
Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For "Niche Busters" And Stem Cells
MUMBAI - Research-related investments funnelled into India by U.S.-based pharmaceutical companies swelled by 10 times between 2002 and 2009 to reach $121 million, a number that will continue to grow in the years to come, according to an upcoming study by the Boston Consulting Group. The report, which was commissioned by the USA-India Chamber of Commerce (USAIC), will be released June 23 during the annual USA-India BioPharma & Healthcare Summit in Boston